The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

The prevalence of fatigue among patients with chronic obstructive pulmonary disease (COPD) worldwide is approximately 59%, according to systematic review and meta-analysis findings published in ...

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

Compare ADHD medications Vyvanse (lisdexamfetamine) vs. Concerta (methylphenidate). Understand their similarities and ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

The Europe Antibiotics Market is witnessing steady growth, driven by the increasing prevalence of infectious diseases, an aging population, and advancements in diagnostic capabilities. These factors ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...

Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. A sustained ...

The global acute respiratory distress syndrome (ARDS) treatment market was valued at approximately USD $$ billion in 2022 and is expected to grow at a robust CAGR of more than $% during the forecast ...

Global health projections indicate that COPD will affect approximately 600 ... This discovery suggests these drugs offer benefits beyond their primary role in blood sugar management.

The study found people with type 2 diabetes who are receiving treatment with GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups compared to those taking DPP-4 drugs.